Trastuzumab (Herceptin, Ogivri, Ontruzant, Trazimera, Herzuma)
Immunotherapy · Approved since 1998
Description
Trastuzumab is a monoclonal antibody that targets HER2-positive colorectal cancer, a rare subtype representing approximately 2-5% of all CRC cases. In metastatic HER2-positive colorectal cancer, trastuzumab is used in combination with other agents such as tucatinib and chemotherapy regimens like mFOLFOX6 as first-line treatment. The drug has shown efficacy in HER2-amplified colorectal tumors, particularly when combined with other HER2-targeted therapies in dual HER2 blockade strategies.
Mechanism of Action
Trastuzumab binds specifically to the extracellular domain of the HER2 receptor (human epidermal growth factor receptor 2), blocking HER2-mediated cell signaling pathways that promote cancer cell growth and survival. By binding to HER2, it prevents receptor dimerization and downstream activation of PI3K/AKT and MAPK pathways, leading to reduced tumor cell proliferation and enhanced apoptosis. The antibody also recruits immune effector cells through antibody-dependent cellular cytotoxicity (ADCC).
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Herceptin, Ogivri, Ontruzant, Trazimera, Herzuma |
| Category | Immunotherapy |
 Status | Off-label |
 EMA Status | EMA Approved |
 Spain Access | Hospital use off-label in CRC |
| Administration | IV |
| Year Approved | 1998 |
| Clinical Trials | 43 |
Regimens with this Drug
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.